Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

valent biosciences a div of sumitomo chemical australia - gibberellic acid - suspension concentrate - gibberellic acid plant growth regulator active 40.0 g/l - plant regulator - apricot | mandarin | navel orange | nectarine | peach - fruit thinning | reduction in flowering and fruiting | fruit thinning

Canada - English - Health Canada

eli lilly canada inc - insulin injection human biosynthetic; insulin isophane human biosynthetic - suspension - 30unit; 70unit - insulin injection human biosynthetic 30unit; insulin isophane human biosynthetic 70unit - insulins

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - warfarin sodium - oral tablet - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - warfarin sodium - oral tablet - 3mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - warfarin sodium - oral tablet - 5mg

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin, quantity: 100 iu/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; metacresol; hydrochloric acid; glycerol - other conditions: refrigerate - do not freeze. indications: for the treatment of insulin dependent diabetic patients.

European Union - English - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - pegfilgrastim - neutropenia - immunostimulants, - reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

European Union - English - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - trastuzumab - stomach neoplasms; breast neoplasms - antineoplastic agents - breast cancermetastatic breast cancerogivri is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatmentsin combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitablein combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic diseasein combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive mbc, not previously treated with trastuzumab.early breast cancer                     ogivri is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc):following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable)following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxelin combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.in combination with neoadjuvant chemotherapy followed by adjuvant ogivri therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.ogivri should only be used in patients with metastatic or ebc whose tumours have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.metastatic gastric cancerogivri in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with her2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.ogivri should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc2+ and a confirmatory sish or fish result, or by an ihc 3+ result. accurate and validated assay methods should be used.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

valent biosciences a div of sumitomo chemical australia - (s)-methoprene; bacillus thuringiensis subsp. israelensis - granular formulation - (s)-methoprene terpene active 1.0 g/kg; bacillus thuringiensis subsp. israelensis biological-organism-bt-israele active 400.0 itu/mg - insecticide

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: water for injections; sodium hydroxide; protamine sulfate; phenol; dibasic sodium phosphate heptahydrate; glycerol; metacresol; hydrochloric acid; zinc oxide - for the treatment of insulin dependent diabetic patients.